Get the Stockscreener App
71.74
0.64%
0.3889
Boston Scientific Corp stock is traded at $71.74, with a volume of 5.50M.
It is up +0.64% in the last 24 hours and down -3.12% over the past month.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
See More
Previous Close:
$71.35
Open:
$70.32
24h Volume:
5.50M
Relative Volume:
0.40
Market Cap:
$106.44B
Revenue:
$20.08B
Net Income/Loss:
$2.89B
P/E Ratio:
37.00
EPS:
1.9391
Net Cash Flow:
$3.66B
1W Performance:
-5.79%
1M Performance:
-3.12%
6M Performance:
-33.57%
1Y Performance:
-27.56%
1-Day Range:
$69.52
$72.11
1-Week Range:
$69.52
$76.37
52-Week Range:
$69.52
$109.50
Boston Scientific Corp Stock (BSX) Company Profile
Name
Boston Scientific Corp
Sector
Industry
Phone
508-683-4000
Address
300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA
Compare BSX vs ABT, SYK, MDT, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BSX
Boston Scientific Corp
|
71.73 | 105.88B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
ABT
Abbott Laboratories
|
111.75 | 190.38B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
362.43 | 139.51B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
90.56 | 116.71B | 35.48B | 4.64B | 5.41B | 3.582 |
|
EW
Edwards Lifesciences Corp
|
83.41 | 47.42B | 6.07B | 1.06B | 1.34B | 1.8063 |
Boston Scientific Corp Stock (BSX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-03-25 | Downgrade | Erste Group | Buy → Hold |
| Sep-08-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-16-25 | Initiated | Leerink Partners | Outperform |
| Apr-16-25 | Upgrade | Needham | Hold → Buy |
| Jan-10-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Oct-18-24 | Downgrade | Needham | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Feb-01-24 | Upgrade | Mizuho | Neutral → Buy |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| Jun-30-23 | Initiated | CL King | Buy |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| Mar-29-23 | Initiated | UBS | Buy |
| Dec-22-22 | Initiated | Mizuho | Neutral |
| Dec-20-22 | Resumed | Citigroup | Buy |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-06-22 | Initiated | Wolfe Research | Outperform |
| May-27-22 | Upgrade | Needham | Hold → Buy |
| Apr-13-22 | Resumed | Truist | Buy |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| May-26-21 | Downgrade | Needham | Buy → Hold |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Sep-17-20 | Initiated | Truist | Buy |
| Sep-11-20 | Initiated | Wolfe Research | Peer Perform |
| Apr-22-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-01-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Buy |
| Dec-30-19 | Reiterated | Cowen | Outperform |
| Dec-19-19 | Downgrade | Needham | Strong Buy → Buy |
| Sep-05-19 | Resumed | JP Morgan | Overweight |
| Sep-03-19 | Resumed | Barclays | Overweight |
| May-13-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-28-18 | Initiated | UBS | Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Oct-02-18 | Reiterated | Morgan Stanley | Overweight |
| Sep-07-18 | Reiterated | Needham | Strong Buy |
| Sep-04-18 | Upgrade | Jefferies | Hold → Buy |
| Jul-06-18 | Reiterated | Needham | Strong Buy |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Apr-26-18 | Reiterated | Needham | Strong Buy |
View All
Boston Scientific Corp Stock (BSX) Latest News
Bronstein, Gewirtz & Grossman LLC Urges Boston Scientific Corporation Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.
BSX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Boston Scientific (BSX) Investors of Securities Class Action Deadline on May 4, 2026 - TMX Newsfile
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Boston Scientific Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Boston Scientific Investor Sues Over Growth Projections - Law360
Boston Scientific Overpromised Segment’s Performance, Suit Says - Bloomberg Law News
BSX Investors Have Opportunity to Lead Boston Scientific Corporation Securities Fraud Lawsuit - Financial Times
BSX Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Boston Scientific Corporation – Company AnnouncementFT.com - Financial Times
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Boston Scientific Corporation (BSX) - marketscreener.com
Boston Scientific’s ENTRUST Registry Targets Real-World Edge in Carotid Stroke Prevention - TipRanks
Why Is Boston Scientific (BSX) Down 6% Since Last Earnings Report? - Yahoo Finance
Boston Scientific to explain new ACC heart data to investors - Stock Titan
Boston Scientific to host investor event at the 75th Annual Scientific Session of the American College of Cardiology - Financial Times
Investor Notice: Robbins LLP Informs Investors of the Boston Scientific Corporation Class Action Lawsuit - The AI Journal
Boston Scientific (BSX) Advances While Market Declines: Some Information for Investors - Yahoo Finance
3 Reasons Boston Scientific Stock Could Quietly 5X as the World Ages - Nasdaq
Boston Scientific (BSX) Raises Share Buyback Authorization To $5B - Finviz
Is It Time To Reconsider Boston Scientific (BSX) After The Recent Share Price Pullback - Yahoo Finance
Boston Scientific Target of Unusually Large Options Trading (NYSE:BSX) - MarketBeat
Boston Scientific : 3 ways we're reducing the environmental impact of our devices - marketscreener.com
Boston Scientific stock hits 52-week low at 72.63 USD - Investing.com South Africa
TD Cowen reiterates Boston Scientific stock rating on guidance confidence - Investing.com
Boston Scientific Corporation $BSX Shares Sold by Teachers Retirement System of The State of Kentucky - MarketBeat
BSX Earnings History & Surprises | EPS & Revenue Results | BOSTON SCIENTIFIC CORP (NYSE:BSX) - ChartMill
Boston Scientific: Near-Term EP Reset but 2027 Growth Drivers Support Buy Rating - TipRanks
1 Healthcare Stock to Target This Week and 2 Facing Challenges - Finviz
Penumbra Sale To Boston Scientific Puts Focus On Deal Terms And Future - simplywall.st
Boston Scientific (BSX) SVP converts RSUs, withholds 372 shares for taxes - Stock Titan
Boston Scientific (NYSE: BSX) Explains Rationale for Penumbra Deal - Stock Titan
Boston Scientific Corp Stock Moved Down by 3.32% on Mar 3: Facts Behind the Movement - TradingKey
Boston Scientific Corp. Experiences Evaluation Revision Amid Mixed Market Signals - Markets Mojo
Boston Scientific Corp.: Why This Quiet Medtech Giant Matters to You - AD HOC NEWS
Segall Bryant & Hamill LLC Has $23.51 Million Position in Boston Scientific Corporation $BSX - MarketBeat
The Zacks Analyst Blog Highlights Apple, TotalEnergies, Boston Scientific and Good Times Restaurants - Bitget
Boston Scientific gets Farapulse label expansion in Europe - Yahoo Finance
Boston Scientific Corp.: Why This Quiet Medtech Giant Is Suddenly On Watch - AD HOC NEWS
FDA recalls Boston Scientific stents, following three deaths, 160+ serious injuries - Worcester Business Journal
Boston Scientific wins expanded CE mark for Farapulse in persistent AFib - MassDevice
Boston Scientific Corporation (BSX) Stock Analysis: With a 36.3% Potential Upside, Is It Time to Invest? - DirectorsTalk Interviews
Andra AP fonden Buys 18,900 Shares of Boston Scientific Corporation $BSX - MarketBeat
111 Capital Makes New Investment in Boston Scientific Corporation $BSX - MarketBeat
Boston Scientific (BSX): Buy, Sell, or Hold Post Q4 Earnings? - Finviz
Levi & Korsinsky Investigates Possible Securities Fraud by Boston Scientific Corporation (BSX) - marketscreener.com
Austin InnoA huge medtech acquisition | Mental health startup launches subscription - The Business Journals
Vaginal Mesh Lawsuit Settlements | March 2026 Update - Lawsuit Information Center
TIAA Trust National Association Has $19.28 Million Stock Position in Boston Scientific Corporation $BSX - MarketBeat
Boston Scientific Corporation $BSX Stock Holdings Raised by Egerton Capital UK LLP - MarketBeat
American Century Companies Inc. Has $390.43 Million Stock Holdings in Boston Scientific Corporation $BSX - MarketBeat
Boston Scientific (BSX) Ascends While Market Falls: Some Facts to Note - Yahoo Finance
Boston Scientific (NYSE: BSX) EVP logs 6,851-share 401(k) rebalancing move - Stock Titan
Boston Scientific Corp. stock outperforms competitors on strong trading day - MarketWatch
Handelsbanken Fonder AB Sells 124,031 Shares of Boston Scientific Corporation $BSX - MarketBeat
Boston Scientific Corp Stock (BSX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
1.92%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):